Wyeth v. Abbott: One Species, Tens of Thousands of Claims, and Undue Experimentation

Wyeth and Cordis Corp. v. Abbott Laboratories, Nos. 2012-1223, -1224 (Fed. Cir. June 26, 2013), is a foundational modern application of the Wands undue-experimentation analysis to a functional genus claim. Writing for the panel, Judge Moore affirmed summary judgment that Wyeth’s restenosis patents were not enabled: the specification disclosed a single working compound, sirolimus, yet the claims reached every “rapamycin” with the desired biological effects — a class the court counted in the tens of thousands. Decided a decade before Amgen v. Sanofi, Wyeth anticipated the Supreme Court’s reasoning and remains a clean, frequently cited template for how courts measure experimental burden against claim breadth.

At a glance

• Case: Wyeth and Cordis Corp. v. Abbott Laboratories, Nos. 2012-1223, -1224
• Court and date: U.S. Court of Appeals for the Federal Circuit; decided June 26, 2013 (precedential)
• Panel: Judges Moore (author), Bryson, and Wallach
• Patents: U.S. Patent Nos. 5,516,781 and 5,563,146
• Holding: The asserted claims are invalid for lack of enablement under 35 U.S.C. § 112; the experimentation required to practice the full claim scope was undue
• Status: Final

The invention and the claims

Wyeth’s patents described a discovery of real therapeutic importance: that rapamycin can treat or prevent restenosis — the renarrowing of an artery after a procedure such as angioplasty. The independent claims recited a method of treating or preventing restenosis by administering “an antirestenosis effective amount of rapamycin.”

The decisive question was what “rapamycin” meant. Wyeth argued for the single compound now known as sirolimus. The district court, however, construed “rapamycin” to embrace a class of compounds sharing a macrocyclic triene ring structure and the claimed immunosuppressive and antirestenotic activity. Under that construction — which the Federal Circuit accepted for purposes of the appeal — the claims covered not one molecule but a functionally defined genus: any compound with the core ring and the desired biological effects. The specification, by contrast, disclosed only sirolimus. It described how to make and use that one species and said essentially nothing about which structural variations would preserve the activity.

The enablement framework

Enablement under § 112(a) requires that the specification teach a skilled artisan to make and use the full scope of the claimed invention without undue experimentation. Whether experimentation is “undue” is assessed under the eight In re Wands factors: the quantity of experimentation needed, the amount of guidance presented, the presence or absence of working examples, the nature of the invention, the state of the prior art, the relative skill of those in the art, the predictability of the art, and the breadth of the claims.

The court did not treat these as a checklist to be tallied; it asked whether, taken together, they showed that practicing the full claimed genus would demand excessive effort. Two factors dominated: the extraordinary breadth of the claims (a genus of tens of thousands of compounds) and the unpredictability of the relationship between a rapamycin analog’s structure and its biological activity.

Why the experimentation was “undue”

Abbott’s evidence, largely uncontested, established the scale of the problem. The claimed class contained at least tens of thousands of structurally distinct compounds. To know which of them actually possessed the claimed immunosuppressive and antirestenotic effects, a researcher would have to make each candidate and then assay it. Wyeth’s own expert conceded that running the relevant assays would take a skilled technician weeks per compound.

Crucially, the specification offered no shortcut. It gave no guidance about which substitutions on the macrocyclic ring would tend to preserve activity and which would destroy it, and no predictive principle that would let a researcher narrow the field before synthesizing and testing. The art was unpredictable, so a skilled artisan could not reason from sirolimus to the rest of the genus; each member had to be confirmed empirically.

The court drew a careful distinction that has become a fixture of enablement law. The mere existence of routine screening assays does not save a claim. Even if each individual experiment is conventional, the aggregate burden can be undue when the number of compounds to be made and tested is vast and the specification supplies no way to predict which will work. Synthesizing and screening tens of thousands of candidates, with weeks of assay work apiece and no predictive guidance, was the paradigm of excessive experimentation. The claims were therefore not enabled.

A precursor to Amgen

Wyeth reads, in retrospect, like a chemical-arts rehearsal for Amgen v. Sanofi. Both cases involve a functional genus — antibodies defined by what they bind in Amgen, rapamycin compounds defined by their effects here — and both fail because the specification offered a method of trial-and-error discovery rather than a teaching of the full claimed class. The Supreme Court’s phrase in Amgen, that “the more a party claims, the more it must enable,” is simply a compact statement of what the Wyeth panel did with the Wands factors. For practitioners, Wyeth remains valuable precisely because its facts are so concrete: a single disclosed species, a clearly quantified genus, and an expert’s own admission about how long the screening would take.

Open questions

Wyeth does not tell us how much structural guidance would have been enough to carry the genus, nor how predictable the structure-activity relationship must be before a representative disclosure suffices. It also leaves open the role of claim construction as a release valve: had “rapamycin” been construed to mean only sirolimus, the enablement problem would have largely evaporated, which is a reminder that the breadth a patentee fights for in construction is the breadth its disclosure must then support. And because the case was resolved on enablement, it does not address how the same claims would have fared under written description — though the reasoning suggests they would have struggled there too.

Implications

• Quantify before you claim broadly. If a functional genus encompasses tens of thousands of compounds and activity must be confirmed one at a time, the claim is exposed to an undue-experimentation defense.
• Routine does not mean sufficient. Disclosing a standard assay protocol does not enable a genus when the number of candidates is enormous; courts weigh the total experimental burden, not the difficulty of any single test.
• Sell structure-activity guidance, not just a species. Teaching which substitutions preserve the desired activity is what converts a single working example into support for a class.
• Construction is destiny. The broader the meaning a patentee secures for a genus term, the heavier the disclosure burden it assumes; narrow, well-supported claims survive.

Frequently asked questions

What did the claims cover that the specification did not teach? The claims covered a genus of rapamycin compounds — on the order of tens of thousands — sharing a macrocyclic triene ring and the claimed biological activity. The specification disclosed and taught only one of them, sirolimus, with no guidance on which other compounds would work.

If the assays were routine, why was the experimentation “undue”? Because undueness turns on the total burden. Even routine assays become excessive when a researcher must synthesize and test tens of thousands of compounds — weeks per assay — with no way to predict in advance which will have the desired effect.

How is Wyeth still relevant after Amgen v. Sanofi? Wyeth (2013) applied the Wands factors to invalidate a functional genus on the same logic the Supreme Court later embraced in Amgen (2023). It offers a concrete, citable example of full-scope enablement analysis in the small-molecule and chemical context.

Authorities and sources

• Wyeth and Cordis Corp. v. Abbott Laboratories, Nos. 2012-1223, -1224 (Fed. Cir. June 26, 2013). Docket numbers, decision date, and precedential status confirmed via Justia and the opinion PDF.
• Panel composition (Moore, Bryson, Wallach), the ‘781 and ‘146 patents, the sirolimus/rapamycin-genus construction, the “tens of thousands” estimate, and the undue-experimentation holding corroborated by Patent Docs.